Simona Malato

Milan, 20123, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects.

Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects.

Journal: Cancers
Published: February 13, 2025

Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study.

Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study.

Journal: Blood advances
Published: October 01, 2024

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.

Journal: Frontiers in oncology
Published: April 30, 2022

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Journal: Blood advances
Published: July 01, 2019

Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).

Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).

Journal: British journal of haematology
Published: May 21, 2019

Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.

Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.

Journal: PloS one
Published: November 27, 2018

Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.

Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.

Journal: Cancer biomarkers : section A of Disease markers
Published: October 18, 2017

Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.

Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.

Journal: Transfusion
Published: December 01, 2014
Showing 1-8 of 8

Last Updated: 09/26/2026